Research
Hormonal
Once-monthly maridebart is associated with HbA1c reductions of approximately 1.2–1.6 percentage points.
Clinicians can anticipate improvements in glycemic control with maridebart therapy.
StrongSupportsmedium confidence
together with HbA1c reductions of ~1.2–1.6 percentage points.
Why this rating
Based on phase 2 trials, indicating a high level of evidence.
Source
Once-Monthly and Extended-Interval Incretin-, Amylin-, and THRβ-Targeting Therapies for Type 2 Diabetes and Obesity: Clinical Evidence and Development Pipelines
Héctor Iván Saldívar-Cerón · Scientia Pharmaceutica · 2026
other
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →